The European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017 took place on 17–21 June 2017 in Helsinki, Finland. EAACI 2017 offered a unique opportunity to learn about new discoveries and exchange experience with professionals in the field of allergy and clinical immunology. The presentations below discuss several topics on CSU treatment, diagnosis and management within the context of recent studies and clinical trials, such as OPTIMA, EXPLORE and AWARE.
Dr Gordon Sussman discusses the results of the OPTIMA clinical trial, assessing the efficacy of different doses of omalizumab in patients with CSU.
Professor Martin Metz considers the use of biomarkers for the diagnosis, differential diagnosis, disease severity assessment, prognosis and therapy response predictions of CSU.
Dr Alexander Marsland takes a look at the latest real-world data in CSU management, discussing case reports, case series, and the observational studies EXPLORE, ASSURE-CSU and AWARE.